My view (opinion only) is that these results are highly unlikely to be negative and that should trigger a re-rating as much on the implications for the CHF trial as for the potential commercialization for LVAD. We are all gambling here but I think the share price still lags real value given the reduction in risk and increase in potential earnings we have seen over the past two months or so.
Ann: End-Stage HF Results Selected For AHA Scientific Sessions, page-52
-
- There are more pages in this discussion • 36 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
94.0¢ |
Change
-0.060(6.00%) |
Mkt cap ! $1.073B | |||
| Open | High | Low | Value | Volume |
| 99.0¢ | 99.5¢ | 93.5¢ | $5.643M | 5.894M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 72266 | 93.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 94.5¢ | 20000 | 1 |
View Market Depth
| Last trade - 16.10pm 02/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |